Unnamed Pharmaceuticals: 2024 Semi-Annual Report Summary
Unnamed Pharmaceuticals: Semi-Annual Report 2024
Shandong Sinobioway Biomedicine (002581.SZ) released its half-year performance, with a net loss of 29.6149 million yuan, narrowing by 44.91% year-on-year.
Shandong Sinobioway Biomedicine (002581.SZ) released its 2024 semi-annual report, with revenue of 0.21 billion yuan, a year-on-year increase...
Shandong Sinobioway Biomedicine (002581.SZ): Net loss of 296.149 million yuan in the first half of the year, with a narrowing loss compared to the same period last year.
Shandong Sinobioway Biomedicine (002581.SZ) announced its interim report for the first half of 2024, with a reported revenue of 0.211 billion yuan, a year-on-year increase of 0.77%; a net loss attributable to shareholders of the listed company of -29.6149 million yuan, with a narrower year-on-year loss; a non-recurring profit and loss deducted net profit attributable to shareholders of the listed company of -26.9934 million yuan; basic earnings per share of -0.0449 yuan.
The One-year Earnings Decline Has Likely Contributed ToShandong Sinobioway Biomedicine's (SZSE:002581) Shareholders Losses of 48% Over That Period
Shandong Sinobioway Biomedicine (002581.SZ) plans to transfer 26.838% stake in Yingkou Chemical for a listing price of 98.0468 million yuan.
On August 1st, Gelunhui reported that Shandong Sinobioway Biomedicine (002581.SZ) plans to sell 26.8380% equity of Yingkou Yingsheng Chemical Technology Co., Ltd. (hereinafter referred to as “Yingkou Chemical”), held by its wholly-owned subsidiary Shandong Wei Ming Tian Yuan Biotechnology Co., Ltd. (hereinafter referred to as "Wei Ming Tian Yuan"), through public listing on the Shandong Property Rights Trading Center, to further optimize resource allocation, improve asset quality, and increase operational efficiency. The first-time public listing transfer price will not be lower than the assessment value of the target assets by the asset appraisal institution. This equity transfer is planned because the participating company's equity is to be transferred.
Shandong Sinobioway Biomedicine: 2024 Interim Performance Forecast
Shandong Sinobioway Biomedicine (002581.SZ): expected pre-loss of 23 million yuan to 42 million yuan in the first half of the year.
On July 12th, Gelunhui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced its performance forecast for the first half of 2024, with a net loss of 23-42 million yuan attributable to shareholders of listed companies, compared with a loss of 53.7573 million yuan in the same period last year; the net loss after deducting non-recurring gains and losses is 20.4-39.4 million yuan, compared with a loss of 48.1417 million yuan in the same period last year; the basic earnings per share were a loss of 0.0349 yuan/share to 0.0637 yuan/share. The reason for the company's loss during the reporting period was due to the decrease in the investment income of the company, and the company will further carry out a new round of global strategic development.
Some Confidence Is Lacking In Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) P/S
Unnamed Pharmaceutical (002581.SZ) withdraws from Qianhai Weiming M&A Fund
Unnamed Pharmaceutical (002581.SZ) issued an announcement, and the company held the 5th term of directors on May 30, 2024...
Unnamed Pharmaceutical (002581.SZ) received a dividend of 215 million yuan from the participating company Beijing Kexing
Unnamed Pharmaceutical (002581.SZ) announced that the company received a shareholding company, Beijing Kexing Biological Products Co., Ltd. (abbreviation...
Shareholders Have Faith in Loss-making Shandong Sinobioway Biomedicine (SZSE:002581) as Stock Climbs 10% in Past Week, Taking Five-year Gain to 83%
Unnamed Pharmaceutical (002581.SZ): Net loss of 27.704 million yuan in the first quarter
On April 30, Ge Longhui Pharmaceutical (002581.SZ) released its report for the first quarter of 2024, achieving operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net profit attributable to shareholders of listed companies - 27.704 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 28.33 million yuan, and basic earnings per share - 0.042 yuan.
Unnamed Pharmaceutical (002581.SZ) reported first-quarter results with a net loss of 27.7041 million yuan
According to Zhitong Finance App, Unnamed Pharmaceutical (002581.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net loss attributable to shareholders of listed companies was 27.7041 million yuan; net loss attributable to shareholders of listed companies deducted 28.33 million yuan for non-recurring profit and loss; basic loss per share was 0.0420 yuan/share.
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Unnamed Pharmaceuticals (002581.SZ): Shareholder Gao Baolin and his co-actors have not reduced their holdings at the end of the reduction period
Gelonghui, March 4 | Unnamed Pharmaceutical (002581.SZ) announced that the company recently received a “Notice Letter on the Expiration of the Share Reduction Period” issued by shareholder Mr. Gao Baolin and his co-actor Mr. Wang Mingxian. As of the announcement date, the period of this holdings reduction plan had expired, and the company's shareholder Mr. Gao Baolin and his co-actor, Mr. Wang Mingxian, had not reduced their holdings in the company.
Unnamed Pharmaceutical (002581.SZ): Received 53.82 million yuan in dividends from participating companies
Gelonghui, Feb. 5 | Weiming Pharmaceutical (002581.SZ) announced that recently, Shandong Weiming Biomedical Co., Ltd. received a dividend of RMB 53.82 million from the participating company Beijing Kexing Biological Products Co., Ltd. (“Beijing Kexing”).
While Shareholders of Shandong Sinobioway Biomedicine (SZSE:002581) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate
Unnamed Pharmaceutical (002581.SZ): Expected net loss of 240 million yuan to 345 million yuan in 2023
On January 30, Gelonghui Pharmaceutical (002581.SZ) announced that it expects a net loss of 243.39 million yuan to 345.09 million yuan in 2023, after deducting non-net loss of 228.87 million yuan to 330.57 million yuan. According to corporate accounting standards and relevant accounting policy regulations, some long-term assets of the company were tested for impairment based on comprehensive influencing factors such as the company's actual operating conditions, changes in the industry market, and asset operation. The initial judgment was that there may be signs of impairment. According to the company's preliminary estimates, the company is expected to calculate impairment provisions for relevant long-term assets in the 2023 annual report: reduction in fixed assets
Investor Optimism Abounds Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) But Growth Is Lacking
No Data